*Government says decision a clear vote of confidence in UK. LONDON, July 27- GlaxoSmithKline plans 275 million pounds of new investments at three drug manufacturing sites in Britain, signalling its confidence in the country despite last month's vote to leave the European Union. GSK is investing in sites at Barnard Castle, in the north of England, Montrose, in... » Read More
Stocks turned lower Wednesday as investors got defensive ahead of earnings season, rotating into pharmaceuticals and out of techs.
The nation's hospitals will give up $155 billion in future Medicare and Medicaid payments to help defray the cost of President Barack Obama's health care plan, a concession the White House hopes will boost an overhaul effort that's hit a roadblock in Congress.
Stocks rebounded Wednesday after a major selloff in the previous session as earnings season gets into gear.
The historic budget crisis in California could go up in smoke if one organization has its way.
Futures indicated a slightly higher open for Wall Street Wednesday on profit taking after the major selloff the previous day.
This sector offers long-term growth, even in a slowdown. Even oil can’t promise that.
Perhaps reflecting concerns about the size and growth of the market for HPV shots and GSK's late entry, investors are not enthusiastic about the prestigious publication of the company's robust new test results. As I write this, GSK shares are the biggest percentage loser in big pharma.
Could a carrot-chomping Bugs Bunny become a drug pitchman? Well, maybe, if the small Israeli company Protalix BioTherapeutics could pay Warner Brothers enough money for Bugs' services.
Today the Food and Drug Administration announced that Pfizer's Chantix and GlaxoSmithKline's Zyban will carry new warnings about mental side effects. Not just any old warnings, but so-called "Black Box" warnings. Or, at least, that's what we in the news media used to call them. Until the FDA called us out today.
Shares of Sanofi-Aventis are getting a little investor injection on the back of the emergency release of the Lantus diabetic insulin studies late last Friday.
Shares of the French drugmaker are getting pummeled over at least three analyst reports identifying a leak about a study or studies that could go public soon. Their research suggests the data is related to a suspected or "theoretical" higher cancer risk associated with SNY's Lantus.
Man, it's gotta hurt when the publicly-traded company you've been leading for years announces you're stepping down and investors pop the champagne corks.
ACC, ADA, AHA, ASCO, ICAD, TCT. That's just a handful of the acronyms and abbreviations for scientific and medical conferences that I've attended over the years. But this year I might be able to add RITA to my dance card. I'd never heard of her (it) before this morning when I got this press release from Crucell, which owns technology for faster, better, cheaper vaccine manufacturing.
The growing, influential role of Twitter has never been more evident than during the recent Iranian uprising. But did the story that "The Wall Street Journal" broke last Friday night about Apple's Steve Jobs getting a liver transplant actually appear on Twitter first?
Cramer, ever the contrarian, disagrees with that sentiment. He prefers his stocks at a different temperature.
Healthcare stocks rebound, so is significant reform dead? Healthcare stocks have been moving off their lows since Tuesday and are up significantly today after moving almost straight down in June.
Two days after the FDA ordered Matrixx Initiatives' Zicam off the market the story remains one of the most emailed articles on "The New York Times" website. And the company seems to still be trying to find its corporate crisis footing.
Wondering what happened to the rally? Cramer puts stocks’ sudden declines into perspective.
I was an early adopter of Zicam when it came on the market 10 years ago. Whenever I felt a cold coming on, I'd load up on the stuff along with Vitamin C and zinc lozenges. So, last night I went searching through the bathroom cabinets to find my Zicam stash to toss it in the trash per the FDA's advisory.
While the charts say one thing, Cramer thinks something entirely different.